PPIG and autoimmune disease: Thus, clazakizumab did not increase CYP metabolism because the included patients had unaltered CYP expression, as ABMR may be different from other disease states, such as infection or autoimmune disease, where systemic inflammation is present (Mühlbacher et al., 2021).